Ebola Treatments Trial Begins in DR Congo
The randomized trial will test MBP134 and remdesivir in up to 1,200 patients as officials seek treatments for a strain with no approved therapy.
- On Thursday, July 2, 2026, the World Health Organization launched the PARTNERS clinical trial in the Democratic Republic of the Congo, enrolling the first patient to test experimental treatments for the Bundibugyo Ebola strain.
- With more than 1,400 cases and nearly 440 deaths reported since May, the Bundibugyo strain remains difficult to treat as clinicians currently lack any approved vaccines or therapies for this rare virus.
- Supplies of the antibody MBP134 and the antiviral remdesivir, donated by U.S. authorities and Gilead Sciences, are being used in a study requiring more than 1,000 participants to assess efficacy.
- Operational hurdles, including widespread community mistrust and violent attacks on medical facilities, continue to complicate the response, WHO Director-General Tedros Adhanom Ghebreyesus noted.
- The adaptive trial platform aims to generate definitive evidence in months rather than years, potentially speeding future responses to Ebola and Marburg outbreaks.
105 Articles
105 Articles
In the Democratic Republic of Congo, the first clinical tests against the rare Ebola variant Bundibugyo begin. Two antiviral therapies are to be tested for their effectiveness. By Karin Bensch.
With 447 dead and 1,460 infected, the outbreak surpasses all previous Bundibugyo variant. Medical teams are attacked by militias on the ground.
DR Congo Begins Ebola Treatment Trial
The Ebola outbreak in the Democratic Republic of Congo is intensifying. With over 1,400 cases and 438 deaths tainting the morale of health workers, there is a small piece of good news. A treatment trial has begun. The DR Congo has officially started a trial of potential treatments for the species of virus behind the current deadly Ebola outbreak in the Democratic Republic of Congo. The strain, called Budibugyo, has been difficult to treat since …
Health authorities in the DRC reported that 595 people remain under treatment, while 213 managed to recover from the disease.
WHO launches PARTNERS clinical trial for Bundibugyo virus treatments
In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.
Coverage Details
Bias Distribution
- 37% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
